An AI-Powered Blood Test to Detect Cancer Using NanoDSF

March 15, 2021

Tsvetkov, P., Eyraud, R., Ayache, S., et al.

Cancers 2021, vol: 13(6) doi: 10.3390/cancers13061294


Glioblastoma is the most frequent and aggressive primary brain tumor. Its diagnosis is based on resection or biopsy that could be especially difficult and dangerous in the case of deep location or patient comorbidities. Monitoring disease evolution and progression also requires repeated biopsies that are often not feasible. Therefore, there is an urgent need to develop biomarkers to diagnose and follow glioblastoma evolution in a minimally invasive way. In the present study, we described a novel cancer detection method based on plasma denaturation profiles obtained by a non-conventional use of differential scanning fluorimetry. Using blood samples from 84 glioma patients and 63 healthy controls, we showed that their denaturation profiles can be automatically distinguished with the help of machine learning algorithms with 92% accuracy. Proposed high throughput workflow can be applied to any type of cancer and could become a powerful pan-cancer diagnostic and monitoring tool requiring only a simple blood test.

View Publication

Topics: Prometheus, nanoDSF, Publications

Previous Video
DLS easily explained: What it tells you about your protein
DLS easily explained: What it tells you about your protein

Join this webinar to learn about the physical phenomenon that drives Dynamic Light Scattering (DLS), and se...

Up next
Automate your screening workflow for characterizing protein stability
Automate your screening workflow for characterizing protein stability

Have a question about Prometheus?

Contact Specialist

Sign up to receive
the latest NanoTemper news, product updates, event announcements and more

First Name
Last Name
Company Name
Agree to Subscribe & Privacy Policy*
*I have fully read, understood and agree to the Privacy Policy. I accept the storing and processing of my personal data by NanoTemper as described in the Privacy Policy.

By completing this form, you provide us consent to contact you with educational content, news and information about our products, services and events. You may unsubscribe at any time.
Thank you!
Error - something went wrong!